Phenylbutazone Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025
The phenylbutazone market has hit a road-block due to its disapproval from the country-wide market in the U.S. However, phenylbutazone, which are nonsteroidal anti-inflammatory drugs (NSAID) that are useful in treating pain, fever, menstrual cramps, arthritis, and other inflammations in human body, continue to be used in other parts of the World. Moreover, these drugs are also used by the veterinary department, wherein 23 actively marketed phenylbutazone drugs are FDA approved for usages on horses. These drugs are available in multiple dosage forms, including boluses, oral tablets, pastes, powders, and solutions for intravenous injection. These two factors are expected to help the global phenylbutazone market sustain the demand the forecast period of 2017 to 2025. On the other hand, the availability of newer drugs with considerably reduced adverse effects on the subjects is hindering the growth rate of the market.
This report on the global phenylbutazone market provides in-depth analysis of all the factors that may favor or obstruct the demand in the near future, and includes profiles of a number of vendors currently operating in the market. The report has been prepared using proven research methodologies and aspires to serve as a dependable business document for targeted audiences such as pharmaceuticals manufacturers, research and academic institutions, hospitals and clinics, contract manufacturers, and contract research organizations. The report also segments the market based on application and product type, as well as studies the opportunities available for the vendors in different regions.
Phenylbutazone is a non-steroidal anti-inflammatory drug meant to provide short-term relief from fever and pain. The drug is currently banned in the U.S. and the U.K. for human use, and therefore is largely meant for animal uses. The ban on phenylbutazone was approved due to its severely debilitating side-effects such as reducing the rate of production of white blood cells and causing aplastic anemia. It was originally used in humans for the treatment of gout and rheumatoid arthritis till 1949 and is now commonly used on horses for the treatment of antipyresis and analgesia.
Phenylbutazone can be administered intravenously or orally but is essentially should only be injected into a vein or administered intramuscularly. Edema and tissue damage may occur if the drug is injected repetitively into the same vein. Side-effects also include oral lesions, blood dyscrasia, kidney damage, GI ulcers, and internal hemorrhage. The drug should also not be used in combination with vitamin K antagonists including warfarin due to the amplifying nature of phenylbutazone on the anticoagulant effect of the antagonists.
The growth in end users in the global phenylbutazone market is expected to occur at an optimistic rate over the coming years, owing to an increase in the consumption of the drug in the growing veterinary medicine industry. In addition, the rising demand for NSAIDs in the emerging economies of Asia Pacific and Latin America is also expected to boost the demand for phenylbutazone over the coming years. However, the high availability of substitutes and the heavy restrictions imposed on the use of phenylbutazone could hamper the growth of this market. Harpagophytum can replace phenylbutazone for treatment of fever and pain in horses.
Asia Pacific is expected to be the leading consumer of phenylbutazone in the world, followed by North America and Europe. China and India are the top consumers of phenylbutazone in Asia Pacific due to presence of highly established end users. Phenylbutazone manufacturers from developed economies are also shifting their base to emerging ones due to the greater availability of government subsidies, land, cheap labor, and a more relaxed regulatory framework. Mongolia, the Republic of Korea, Australia and New Zealand are expected to be key consumers of phenylbutazone in the future. North America and Europe are expected to experience a moderate rate of growth in demand. The demand for phenylbutazone is also expected to increase in Latin American nations due to an increasing demand for veterinary drugs, namely in Argentina, Brazil, Colombia and Peru.
Some of the leaders in the global phenylbutazone market so far, have been Santa Cruz Biotechnology, Inc., Hangzhou Hyper Chemicals Limited, Baoji Guokang Bio-Technology Co., Ltd., Wuhan Yitongtai Science and Technology Co., Ltd., Afine Chemicals Limited, Shanghai Win-Win Biochemical Co., Ltd., Shaanxi TOP Pharm Chemical Co., Ltd., Hangzhou Hyper Chemicals Limited, Hangzhou Ruijiang Chemical Co., Ltd., Dalian Launcher Fine Chemical Co., Ltd., Croma Life Science Pvt. Ltd., Swati Chemicals, Suchem Laboratories, Uni-med India, Afton Pharma, and Hefei TNJ Chemical Industry Co., Ltd.
This study provides a particularized anatomy according to the L.E.A.P mechanism
The regional analysis offers market assays across:
The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.
Latest Trends and Cardinal Growth Prospects
The study assists in burnishing the knowledge of the stakeholder in terms of the emerging trends. The study provides an expansive coverage on the latest developments and novel profit-yielding sources that augur well with the market. A dedicated and determined team of experts conduct an out-and-out research on diverse aspects to offer ultimate breakthroughs in the market.
Existing and Future Insights in Growth
The interfusion of ubiquitous primary and secondary research through modern tools invites perfection and accuracy in every aspect. Primary research is circumspectly conducted through exhaustive interactions and interviews of experts. These valuable opinions are then neatly inducted in the report to allow the stakeholder for reaping the benefits. A treasure of secondary data is extracted via famed paid sources, yearly estimates and statements, renowned journals, and government documents. These sources assist in creating a robust database comprising existing and subsequent growth dynamics.
Ascensions in Technology
Diverse technological advancements and cutting-edge innovations in the market have been covered in this study to assist the stakeholder in research and development activities. Recent upgrades have also been added in the study, thus helping the stakeholder to paint the strokes of growth on the canvas of the market.
The study presents a plethora of challenges and obstacles that can hinder the growth of the market to allow the stakeholder to prepare their strategies accordingly.
The world ushered in the new decade with the shadow of the COVID-19 pandemic. The outbreak has damaged the growth prospects of several businesses and has crippled the entire economy. The study is in tandem with the changing dynamics of the market due to the SARS-CoV-2 outbreak. The study focuses on the coronavirus pandemic and analyses every aspect that impacts the growth positively or negatively.
An aerial perspective of the regions covered in this study enables the stakeholder to design strategies accordingly. The 360-degree assessment of every aspect associated with growth offers information on a rainbow of growth opportunities available across the market.
The exhaustive study motivates the stakeholder to take the 'LEAP' of faith and achieve success!
This report is the key to questions such as:
What are the prominent factors that will help in reshaping the market growth?
Which trends have the potential to bring expansive growth for the market?
What are the necessary strategies to overcome the ill-effects of the COVID-19 pandemic?
Which regions will emerge as champion growth contributors for the market?
Which aspects will serve as game-changers for the market?
What are the latest innovations in the market?
Which factors will hinder the growth of the market?
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report